166 related articles for article (PubMed ID: 29846017)
1. Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94.
Sprenger T; Beißbarth T; Sauer R; Tschmelitsch J; Fietkau R; Liersch T; Hohenberger W; Staib L; Gaedcke J; Raab HR; Rödel C; Ghadimi M
Br J Surg; 2018 Oct; 105(11):1510-1518. PubMed ID: 29846017
[TBL] [Abstract][Full Text] [Related]
2. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Sauer R; Liersch T; Merkel S; Fietkau R; Hohenberger W; Hess C; Becker H; Raab HR; Villanueva MT; Witzigmann H; Wittekind C; Beissbarth T; Rödel C
J Clin Oncol; 2012 Jun; 30(16):1926-33. PubMed ID: 22529255
[TBL] [Abstract][Full Text] [Related]
3. Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
Kitz J; Fokas E; Beissbarth T; Ströbel P; Wittekind C; Hartmann A; Rüschoff J; Papadopoulos T; Rösler E; Ortloff-Kittredge P; Kania U; Schlitt H; Link KH; Bechstein W; Raab HR; Staib L; Germer CT; Liersch T; Sauer R; Rödel C; Ghadimi M; Hohenberger W;
JAMA Surg; 2018 Aug; 153(8):e181607. PubMed ID: 29874375
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
5. Stage-Dependent Frequency of Lymph Node Metastases in Patients With Rectal Carcinoma After Preoperative Chemoradiation: Results from the CAO/ARO/AIO-94 Trial and From a Comparative Prospective Evaluation With Extensive Pathological Workup.
Sprenger T; Rothe H; Conradi LC; Beissbarth T; Kauffels A; Kitz J; Homayounfar K; Wolff H; Ströbel P; Ghadimi M; Wittekind C; Sauer R; Rödel C; Liersch T
Dis Colon Rectum; 2016 May; 59(5):377-85. PubMed ID: 27050599
[TBL] [Abstract][Full Text] [Related]
6. [Lymph node metastases in ypT1/2 rectal cancer after neoadjuvant chemoradiotherapy : The Achilles heel of organ-preserving operative procedures?].
Sprenger T; Rothe H; Beissbarth T; Conradi LC; Kauffels A; Homayounfar K; Behnes CL; Rödel C; Liersch T; Ghadimi M
Chirurg; 2016 Jul; 87(7):593-601. PubMed ID: 27106241
[TBL] [Abstract][Full Text] [Related]
7. Multicentre analysis of oncological and survival outcomes following anastomotic leakage after rectal cancer surgery.
den Dulk M; Marijnen CA; Collette L; Putter H; Påhlman L; Folkesson J; Bosset JF; Rödel C; Bujko K; van de Velde CJ
Br J Surg; 2009 Sep; 96(9):1066-75. PubMed ID: 19672927
[TBL] [Abstract][Full Text] [Related]
8. Oncological outcome after MRI-based selection for neoadjuvant chemoradiotherapy in the OCUM Rectal Cancer Trial.
Ruppert R; Junginger T; Ptok H; Strassburg J; Maurer CA; Brosi P; Sauer J; Baral J; Kreis M; Wollschlaeger D; Hermanek P; Merkel S;
Br J Surg; 2018 Oct; 105(11):1519-1529. PubMed ID: 29744860
[TBL] [Abstract][Full Text] [Related]
9. Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials.
von den Grün JM; Hartmann A; Fietkau R; Ghadimi M; Liersch T; Hohenberger W; Weitz J; Sauer R; Wittekind C; Ströbel P; Rödel C; Fokas E;
Radiother Oncol; 2018 Sep; 128(3):557-563. PubMed ID: 29929861
[TBL] [Abstract][Full Text] [Related]
10. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial.
Fujita S; Akasu T; Mizusawa J; Saito N; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Shiozawa M; Yamaguchi T; Moriya Y;
Lancet Oncol; 2012 Jun; 13(6):616-21. PubMed ID: 22591948
[TBL] [Abstract][Full Text] [Related]
11. Overall Survival After Treatment Failure Among Patients With Rectal Cancer.
Diefenhardt M; Martin D; Fleischmann M; Hofheinz RD; Ghadimi M; Rödel C; Fokas E
JAMA Netw Open; 2023 Oct; 6(10):e2340256. PubMed ID: 37902752
[TBL] [Abstract][Full Text] [Related]
12. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial.
Fokas E; Liersch T; Fietkau R; Hohenberger W; Beissbarth T; Hess C; Becker H; Ghadimi M; Mrak K; Merkel S; Raab HR; Sauer R; Wittekind C; Rödel C
J Clin Oncol; 2014 May; 32(15):1554-62. PubMed ID: 24752056
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials.
Diefenhardt M; Fleischmann M; Martin D; Hofheinz RD; Piso P; Germer CT; Hambsch P; Grützmann R; Kirste S; Schlenska-Lange A; Ghadimi M; Rödel C; Fokas E;
Radiother Oncol; 2023 Feb; 179():109455. PubMed ID: 36572280
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.
Akgun E; Caliskan C; Bozbiyik O; Yoldas T; Sezak M; Ozkok S; Kose T; Karabulut B; Harman M; Ozutemiz O
Br J Surg; 2018 Oct; 105(11):1417-1425. PubMed ID: 30155949
[TBL] [Abstract][Full Text] [Related]
15. Surgery for locally recurrent rectal cancer in the era of total mesorectal excision: is there still a chance for cure?
Rahbari NN; Ulrich AB; Bruckner T; Münter M; Nickles A; Contin P; Löffler T; Reissfelder C; Koch M; Büchler MW; Weitz J
Ann Surg; 2011 Mar; 253(3):522-33. PubMed ID: 21209587
[TBL] [Abstract][Full Text] [Related]
16. Lymph node metastases in rectal cancer after preoperative radiochemotherapy: impact of intramesorectal distribution and residual micrometastatic involvement.
Sprenger T; Rothe H; Becker H; Beissbarth T; Homayounfar K; Gauss K; Kitz J; Wolff H; Scheel AH; Ghadimi M; Rödel C; Conradi LC; Liersch T
Am J Surg Pathol; 2013 Aug; 37(8):1283-9. PubMed ID: 23851331
[TBL] [Abstract][Full Text] [Related]
17. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
18. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
[TBL] [Abstract][Full Text] [Related]
19. Multicentre study of robotic intersphincteric resection for low rectal cancer.
Park JS; Kim NK; Kim SH; Lee KY; Lee KY; Shin JY; Kim CN; Choi GS;
Br J Surg; 2015 Nov; 102(12):1567-73. PubMed ID: 26312601
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of Laparoscopic Total Mesorectal Excision with Extended Lateral Pelvic Lymph Node Dissection for Advanced Lower Rectal Cancer after Preoperative Chemoradiotherapy.
Ogura A; Akiyoshi T; Nagasaki T; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Kuroyanagi H
World J Surg; 2017 Mar; 41(3):868-875. PubMed ID: 27730352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
